Life Sciences Archive » November, 2020

Life Sciences - November, 2020

330 articles

• Henry Thayer Co. Accused Of False 'Natural' Claims
• Judge Won't Quickly Pause Discovery In Shkreli's FTC Case
• 30 AGs Back $465M J&J Verdict In Landmark Opioid Trial
• Gov't Contracts Of The Month: Vaccines, Arms, Cloud Awards
• DoorDash Preps $2.6B IPO As December Blitz Gets Underway
• Bayer Hits Generic Co. With Another Hypertension Drug Suit
• PharMerica Beats Whistleblower's FCA Claims Over 'Swapping'
• Europe Hits Teva With €60M Fine Over Pay-For-Delay Deal
• Anticipating The Biden Administration's Health Care Agenda
• 7 Tips For Predeposition Meetings Under New Federal Rule
• AbbVie Gets Humira Kickbacks FCA Suit Limited To Florida
• How To Prepare For Congressional Investigations In 2021
• 11th Circ. OKs Sanctions Against Ex-Stryker Salesperson
• Coherus Loses Bid To Shift Fees To Amgen In Patent Suit
• Moderna Seeks FDA Approval For COVID-19 Vaccine
• Greenberg Traurig Taps Ex-HHS Atty For Health Care Practice
• The Firms That Dominated In 2020
• Law360 Names Practice Groups Of The Year
• DNA Sequencing Trial Wraps, Illumina Rival Seeks Invalidity
• Monsanto, BASF Get $265M Dicamba Verdict Slashed To $75M
• Zydus Insists Mitsubishi Doesn't Deserve Diabetes Patents
• EU Regulatory Plan Targets Big Pharma Competition, Mergers
• Appeals Court Says NJ Medical Pot Permit Scoring Is Flawed
• US, Smith & Nephew Urge Justices To Overturn Arthrex
• SmileDirect Tries To Save Calif. Dental Board Suit At 9th Circ.
• GAO Denies Protest Of Vaccine Research Contract
• Goodwin Steers Mass Spectrometry Biz Eyeing $75M IPO
• Coronavirus Regulations: A State-By-State Week In Review
• Sport Supplement Co., Owner Plead Guilty Over Steroids
• Suit Says 'Infant' Fever Drugs Are Same As 'Children' Drugs
• Ethics Reminders As Employees Move To Or From Gov't
• Telehealth Platform Can't Oust Medical Pot Co., Judge Says
• Groups Sue Trump To Block New Drug Import Rule
• Jury Awards $3.5M In Iowa Artificial Hip Trial
• Chancery Slams Gilead Stonewalling Over Records Demands
• No Discrimination Ban For Medical Pot Patients, Hospital Says
• HHS Says It's Working With Biden, Touts AstraZeneca Vaccine
• Mallinckrodt Ch. 11 Pauses Express Scripts Antitrust Claims
• NJ Cannabis Strides Highlight Nearby States' Need To Legalize
• EEOC Nabs $310K Recovery In Race, Sex Harassment Suits
• Surveying Drug Pricing Reform: The Latest State Activity
• Purdue Pleads Guilty In NJ To Criminal Opioid Conspiracy
• Biomet To Pay $21M In Hip Implant Defect Suit Verdict
• Don't Fear IP-Antitrust 'Turducken' In Reverse-Payment Cases
• How Joe Biden Will Change The FDA: Part 2
• Pa. Retailers Accused Of Wrongly Charging Tax On Masks
• USPTO Aims To End Tech Giants' PTAB Denials Challenge
• UK Antitrust Arm Mulling Bipolar Drug Co.'s Commitments
• A Key To Helping Clients Make Better Decisions During Crisis
• Greenberg Traurig Clears Conflict Inquiry In $1B Fraud Case
• Teva's Bid To Duck MDL Trials Slammed As 'Fool's Errand'
• Biotech Co. Defeats Investor Suit Over Short-Seller Reports
• Supplier Sued Over $5.4M In FDA-Barred Sanitizer Wipes
• Fed. Circ. Affirms Hospira's Generic Adrenalin Loss To Par
• Abbott Labs Fights Amended ERISA Claims Over Stolen $245K
• AstraZeneca Finds 90% Vaccine Success, Will Seek Approval
• Merck Again Denied In Bid To Arbitrate Vaccine Antitrust Suit
• HHS Increasing IP License Transparency After GAO Rebuke
• Stericycle Investor Seeks Atty Sanction After Objector Claim
• Texas Law Firm, Mexican Supplier Settle $3M Mask Sale Row
• Latham-Led Life Sciences Co. Debuts With $800M In Backing
• Retailers Accuse Pharma Cos. Of Blocking Generic Bystolic
• How Joe Biden Will Change The FDA: Part 1
• 1st Circ. Backs Convictions For Pharma Inside Traders
• A Forgotten But Effective Tool Against Opioid Scams
• Ethics Considerations For Law Firms Implementing AI
• Feds Say No Privilege For Ex-Theranos CEO In Fraud Case
• Trump Slams Big Pharma In Rollout Of Drug Price Rules
• FDA Targets COVID-19 Claims Over Stem Cell, Dental Products
• Medical Marijuana Co. Sues Law Firm For Malpractice
• WTO Divided Over Suspending Protection Of COVID-19 IP
• Hospital Looks To Block Plan To Boot It From Health Network
• Judge Gives Initial OK To Correvio Pharma $1.75M Class Deal
• Pot Co. Liberty Health Agrees To Settle $1.8M Securities Row
• Pfizer, BioNTech Seek Emergency COVID-19 Vaccine Approval
• Pair Of Health-Focused Cos. Tap Market For $2.7B Via IPOs
• Mallinckrodt Can Use Lender Cash As Ch. 11 Probe Proceeds
• When A Product Liability Case Can't Survive Outside An MDL
• 7th Circ. Backs Ex-Pharma Head's Nearly 3-Year Sentence
• J&J Unit, PE Firm To Pay $11.5M Over FCA Claims
• AstraZeneca Affiliates Duck $275M Merger Payment Suit
• How Federal Virus Liability Law Will Apply To Vaccine Claims
• Health Hires: Epstein Becker, Lewis Brisbois, Taylor English
• UK Litigation Roundup: Here's What You Missed In London
• Picking The Right Location And Tools For Virtual Courtrooms
• Contractor Fights Investors' Claims Over COVID Test Kit Deal
• What To Expect From The USPTO In The Biden Administration
• White House, CDC Call For Vigilance Amid COVID-19 Surge
• Pot Co. Defeats Accountant's Wrongful Termination Claim
• Cannabis Biz Ayr Buys Pa. Medical Pot Grower For $21M
• LinkedIn, Zynga Founders' SPAC Leads 4 Raising $530M Total
• China Biologic Lands $4.76B Value In Take-Private Deal
• Anthem Adds Ex-HCSC Atty As Its General Counsel
• Hospital Can't Escape Suit Over Surgery With Recalled Laser
• Utah Medical Pot Licensing Marred By Bias, Auditor Says
• Coronavirus Litigation: The Week In Review
• 5 Red Flags For Pandemic-Related Investment Scams
• Fed. Circ. Affirms $107M Inhaler IP Judgment Against GSK
• Teva Inks $2.55M Deal To Settle 401(k) Fee Suit
• Beware Atty Ethics Rules When Reporting COVID-19 Fraud
• Latham-Led REIT Lands $1.7B For Life Science Projects
• AmerisourceBergen Held In Contempt In Wash. Opioid Suit
• MiMedx Execs Convicted In SDNY's 1st Virus-Era Fraud Trial
• COVID-19 Tort Cases Aimed Largely At Cruise Lines
• Prof Wins $8M IP Trial Against Health Cos., Convicted Ex-Atty
• Judge Refuses To Halt Biomet Trial After Juror Caught Virus
• Fla. Judge OKs Prevagen Deal After Striking Objection
• Feds Urge Court Not To Ax $300M Teva Kickback Case
• Mallinckrodt Says Order Gives Time For Transfer Probes
• Pa. Appeals Court OKs Benefits For Fired Medical Pot User
• Trump Admin. Touts COVID-19 Vaccine Success, Preps Rollout
• HHS Cancels $15M Celebrity-Filled Virus Campaign After Audit
• Judge Unlikely To Toss Fight Over COVID-19 Biz's Soured Deal
• Ecolab Says Ex-Manager's Rival Biz Used Trade Secrets
• Jury Mulls Fraud Case Against Ex-MiMedx Execs For 3rd Day
• Looking For Judicial Activists? Check The Footnotes
• Ill. City Says Mallinckrodt Ch. 11 Can't Halt Antitrust Claims
• Courts Are Not Confused About Opioid Insurance Suits
• House OKs Bill To Join Global Health Org. Funding Vaccines
• Using Prior Art In Patentability Args Amid Fed. Circ. Confusion
• Best Practices For Legal Technology Adoption
• Del. Judge Pushed Trial Due To Spoliation Claim, Not Virus
• Real Estate Rumors: IQHQ, Longfellow, PulteGroup
• Valuation Uncertainty Could Prompt Increased Litigation
• Judge Strikes Opioid Claims Against Prescribers
• KKR Takes $100M Ownership Stake In NZ Animal Health Co.
• Former Insys Execs Win Another COVID-19 Prison Delay
• Purdue Pharma Gets Court Approval For $8B Deal With Feds
• Abbott Must Face Patent Suit Over Baby Probiotics
• House Passes Bill Targeting Orphan Drug Exclusivity
• Pot Retailers Harvest And Vireo Sell Off Assets In 2 States
• FDA Answers GAO Calls For COVID-19 Vaccine Transparency
• Zetia Buyers Spar With Merck, Glenmark Over Expert Witness
• Amgen, GSK Urge Justices To Allow Patents On Genus Claims
• Fed. Circ. Ruling May Reshape Hatch-Waxman Litigation Map
• FTC Urges 3rd Circ. To Restore $448M AbbVie Penalty
• Wilson Sonsini Scores Ex-New York Antitrust Chief
• Miss. High Court Takes Up Challenge To Medical Pot Measure
• House Passes Bipartisan Bills To Fight Opioid Crisis
• Coronavirus Regulations: A State-By-State Week In Review
• The Pandemic's Long-Term Impact On Law Firm Operations
• How Biden Might Dismantle Trump-Era Regulations
• Cannabis In NJ Can't Work Without Medical Marketplace Fix
• Exec Pleads Guilty, Will Pay $16.5M For Medicare Fraud
• Missing Inventor Doomed Broad's CRISPR Patent At EPO
• 4th Circ. Will Fast-Track Challenge To Zetia Buyers' Class Cert.
• Rejected NJ Pot License Applicants Press AG For Settlement
• Illumina Wants Calif. Court To Double $27M IP Win Over Roche
• 14 Firms To Steer 10 IPOs In Pre-Thanksgiving Rush
• Jury Mulls Case Against Ex-Execs As SDNY Navigates Virus
• USPTO Defends Ax Of Nutrition Supplement IP To Justices
• Ex-HHS Atty Joins McDermott At Key Time For Health Care
• Terns Pharmaceuticals Brings On New Top Lawyer
• Lack Of Access To Remote Court Proceedings Is Inexcusable
• Imerys Gets Nod For $223M Ch. 11 Sale; $30M Loan Delayed
• Feds Say $225M Sackler Fine To Go To Medicare, Medicaid
• In Fraud Alert, HHS Watchdog Urges End To Pharma Events
• DHS Flags Becton Medical Pump For Cybersecurity Issues
• ViSalus Says Lack Of Harm Dooms $925M Robocall Award
• Biogen Investors Say Co. Misled Them On Alzheimer's Drug
• Criminal Charges Should Delay Hemp Dispute, Calif. Says
• Chinese Co.'s US Unit May Get Access To Virus-Testing Patent
• Russia, North Korea Accused Of Hacking Vaccine Research
• Manufacturer Must Face Suit Over Worker's Biometric Data
• Health Org Gets $2B To Give Poor Nations COVID-19 Vaccines
• Another Dem Raises Concerns Over $1B Virus Fund Spending
• 3 Firms Score End-Payor Co-Lead Role In Seroquel XR Cases
• Opioid Expert's Data Belongs In Bellwether Trial, Judge Told
• Why Attacks On Trump's Election Lawyers Are Problematic
• Health Hires: Cozen O'Connor, LumiThera
• FDA, DEA Experts Cleared To Testify In NY AG's Opioid Case
• FDA Must Address Lannett's Lies On Cocaine Drug, Suit Says
• Top WTO Official Wants Tariffs On Medical Supplies Dropped
• Vaccine Developers Must Put Cure Before Patent Profits
• Insulin Pen Buyers Say Sanofi Antitrust Suit Not Overly Broad
• Purdue's $8B Deal Doesn't End Calif.'s Row With Big Pharma
• Coronavirus Litigation: The Week In Review
• Ex-Insys Exec Who Flipped Seeks COVID-19 Prison Delay
• Sanofi Must Face Cancer Drug FCA Claims At Trial
• Supreme Court Urged To Make Arbitration Contracts Binding
• InfoBionic Tells Justices Patent Eligibility Is 'Off The Rails'
• States Say $8.3B Purdue Opioid Deal Flouts Bankruptcy Rules
• Kodak Says Ex-Execs Made $5.1M On Forfeited Stock Options
• State Pot Regulators Join Forces To Share Best Practices
• Justices Told Not To Revisit $268M Hearing Aid Patent Award
• Zetia Buyers Seek To Speed Up Drug Cos.' Class Cert. Appeal
• Avoiding 6 Common E-Discovery Production Pitfalls
• Cleary Steers PE-Backed Sotera Health's $1B IPO Launch
• What To Expect From US Trade Policy In The Biden Era
• Researcher Cops To Hiding China Ties To Win $4M In Grants
• Verano, AltMed Merger Creates Privately Held Pot Giant
• PTAB Mylan Decision Could Be Boon To Drug Innovators
• New Vivus Ch. 11 Plan Offers Stockholders Drug Royalties
• Shkreli's Objections To FTC Prison Comms Access Tossed
• Pfizer Unit Hit With Another Suit Over Tossed Lyrica Patent
• Biden Taps BigLaw Partner, Obama Officials For HHS Review
• Bard Gets Fed. Circ. To Revive $68M Infringement Trial
• 4 Key Moments As Justices Debate ACA's Fate
• GSK Says FDA Rejected Zofran Label Change
• FTC Probes Illumina's $8B Deal For Cancer Detection Biz
• Fed. Circ. Remands Ferring Drug Patent Inventorship Fight
• Pot Co. Seeks High Court Review Of IRS Summons Fight
• Rival Accuses ProMedica Of Anti-Competitive Conduct
• CVS, Rite Aid Say Doctors Also Liable For Prescribing Opioids
• Sterigenics' Suit Over Ga. Plant Shutdown Kept Alive For Now
• Coronavirus Regulations: A State-By-State Week In Review
• Drug Price Checker's Legality Mulled Amid Bid To Toss Suit
• Boehringer To Settle 3K Pradaxa Bleeding Risk Cases
• Citing 'Botox,' TTAB Rejects 'Boto Smart' Trademark
• SEC Wants $15M From Sanofi Insider Trading Suspect
• Edwards Lifesciences Bolsters Tech's Attack On PTAB Denials
• West Pharmaceutical Hires Segal Group GC
• Feds To Take True Health Ch. 11 Plan Appeal To 3rd Circ.
• DEA Hemp Rule Could Lose Edge Under Biden Admin.
• Substantive Issues Plague China's Patent Linkage Regime
• Law Firm Biz Development Tips For The Pandemic Era
• ACA Likely To Survive High Court Ruling On Mandate
• Allied BioScience Says Founder, Ex-CEO Holding IP Hostage
• 4 Key Developments As US Coronavirus Cases Hit 10M
• 9th Circ. Urged To Nix Private Commercial Arbitration Doc Bid
• Grocer Secures Defense Coverage In Opioid Injury Suits
• Chancery Won't Pause Vaxart Insider-Trading Suit In Del.
• Muscogee (Creek) Nation Passes Post-McGirt Marijuana Law
• McKesson Says Ex-Exec's Opioid Guilty Plea Is Inadmissible
• 3M Wins Trial Over Ship Worker's Faulty Respirator Claims
• Customedia Calls For 2nd Shot After Justices Take Up Arthrex
• Biosimilars Caught In Crosshairs Of Supreme Court ACA Fight
• Justices Snub 2 Post-Arthrex Cases, Seek Reply In Another
• Biotech Co. Investors Battle To Lead COVID-19 Vaccine Suit
• Goodwin Procter Guides Biopharma Co.'s $50M IPO Plans
• Texas Law Firm Launches Counterclaims In Mask Sale Fight
• Snell Seeks Sanctions For Ex-NFL Player In Liability Fight
• Dentist's Virus Suit Returned To State Court Despite Protest
• Rulings Show Limits Of Federal Agency Vacancy Law
• Zoll Medical Sues Security Co. Over Major 2018 Data Breach
• Illumina Says Rival Infringes DNA Sequencing IP At Trial Start
• AbbVie Takes Takeda To Chancery Over Lupron Shortfall
• Arsenic, Toxins In Apple Juice Sent To Schools, FDA Says
• What You Need To Know About Biden And IP
• Biden Opioid Plan Puts Pharmacies On Notice
• 5 Key Areas To Watch As 'Bidencare' Takes Shape
• High Court Expansion Unlikely After Tight Election
• Biden Win May Lead To First Black Female Justice
• Biden's Win Means Big Business For BigLaw
• Biden Beats Trump At The Polls As Court Battles Continue
• FDA Panel Won't Back Approval Of Biogen's Alzheimer's Drug
• Becton Says Revived Antitrust Suit Should Be Axed For Good
• 2 Firms Guide REIT, GIC Launch Of JV With $930M Projects
• FDA Must Face Trial In Ex-Worker's Sex Harassment Suit
• PTAB Again Upholds Pfizer Pneumonia Vaccine Patent Claim
• SEC Expands Pfizer Bribery Inquiries Into China
• HHS Opinions Signal Broad Immunity From COVID-19 Liability
• Patent Filings Dropped As Pandemic Gripped US
• Curaleaf To Fund Maryland Growth With $31.5M Pot Asset Sale
• Meet The Attys Arguing ACA's Fate At Supreme Court
• 3 Firms Build Novo Nordisk's $1.8B Emisphere Buy
• Servier Loses Bid To Enforce EU Pay-For-Delay Ruling In UK
• $26B Opioid Deal Offer To Include $2B In Atty Fees
• Testimony In NJ Zoom Trial Wraps In Diabetes Drug IP Row
• Online Pharmacy, Ex-Exec Sue Polsinelli Over SEC Probe Fees
• Inovio Defends Virus Vaccine Claims In Bid To Nix Stock Suit
• Ex-Startup CEO Gets 135 Months For Embezzling $3M
• 4 Things To Know About China's Revised Patent Law
• Fed. Circ. Restricts Venue Options For Hatch-Waxman Suits
• Coronavirus Litigation: The Week In Review
• FDA Must Study Enviro Risks Of Genetically Engineered Fish
• BigLaw Must Drop The Billable Hour To Improve Diversity
• 10th Circ. IRS Summons Ruling Shows Cannabis Biz Dilemma
• Medical Pot Co. Claims Franchisee Sold Bootleg Products
• Medical Pot Biz Vireo Inks Debt Deal Worth Up To $46M
• Merck Plows Ahead With Another Suit Over Diabetes Drug
• Aviation Insurers Must Prep For Vaccine Shipment Risks
• Allergan Can Sue Pfizer To Recoup Opioid Litigation Costs
• Actavis Can't Escape Testosterone Drug Warning Claims
• 3 Bankruptcy Rulings Highlight Barriers For Pot-Adjacent Cos.
• Gibson, Cooley Craft Merck's $2.75B Cancer Therapy Co. Buy
• HHS Floats Plan To 'Sunset' Unnecessary Regulations
• Full Fed. Circ. Won't Reconsider Bio-Rad's $24M IP Verdict
• J&J Slams Imerys' Objection To $20M Claim In Ch. 11 Case
• Merck Says Pfizer's Trade Secrets Counterclaims Are Useless
• Trump Unleashes Barrage Of Lawsuits In Battleground States
• Fla. Biotech Cuts Deal To Develop COVID-19 Vaccine In China
• UnitedHealth Beats Labs' $49M ERISA Suit Over Claim Denials
• Pot's Ballot Victories Bode Well For Reform's Future
• Irish Court Rejects Perrigo's Bid To Quash $1.92B Tax Bill
• Biomet Orthopedics Can't Duck Defective Hip Implant Suit
• McKesson Whistleblowers Fight Bid To Toss Opioid FCA Suit
• Cannabis Biz EMMAC's Blank-Check Deal Falls Through
• Amgen Biosimilar Rows Reveal Manufacturing Patents' Value
• Fed. Circ. Urged To Restore Narcan Patents
• Mont. Voters Approve Measure To Legalize, Tax Marijuana
• South Dakota Voters Pass Pot Legalization Initiative
• Senate Majority Still In Doubt As Races Tighten
• Biden Campaign Plays Down Trump High Court Threat
• Trump Vows To Contest Uncounted Ballots At High Court
• The BigLaw Attorneys Battling Over An Undecided Election
• Don't Look To Bush v. Gore For 2020 Blueprint
• Senate — And Pandemic Relief — Still Hanging In The Balance
• New Jersey, Ariz. Legalize Pot In Ballot Measure Sweep
• Miss. Voters Approve Citizen-Led Medical Marijuana Initiative
• Ore. Voters OK Legalizing Psychedelic Mushroom Substance
• Gilead Says Homeless Recruited To Scam HIV Drug Charity
• NJ Voters Approve Pot Legalization At Ballot
• Generics Cos. Attack 'Serial' Complaints In Price-Fixing Row
• Online Talc Jury Trial Against J&J Ends In Mistrial
• Gov't Entities Seek Probe Of $1B Mallinckrodt Debt Swap
• Coronavirus Regulations: A State-By-State Week In Review
• McKesson, 2 Other Distributors Ink $21B Opioid Settlement
• 4th Circ. Says OK To Zetia Class Certification Challenge
• 3rd Circ. Tosses Defect Claims Over Abbott Artery Device
• Compliance Lessons From DOJ's Merit Medical Settlement
• Bayer Budgets $2B To Settle Future Roundup Cancer Claims
• FTC OKs Stryker's $4B Wright Medical Deal, With Divestitures
• Red States Back FDA Limits On Abortion Pills At 4th Circ.
• Mo. High Court Won't Review $2.1B J&J Talc Verdict
• Fed. Circ. Rejects Email-Deleting Glaucoma Co.'s Plea
• 8 Tips For Effective Oral Advocacy In Virtual Court Hearings
• From The Front Lines: The Attorneys Protecting This Election
• W.Va. Gov'ts Rip Bid To Block Opioid Victims' Testimony
• Guardant Patent Trial Delayed After Virus Safety Objections
• Insys Founder Wants Another Prison Delay Due To COVID-19
• Trump Admin. Expands Efforts To Keep Opioids Out Of US
• AbbVie Wants Hypertension Drug Antitrust Row Sent To NJ
• Justices Skip Case Horizon Said Puts 32K Patents At Risk
• Professor Says Parkinson's Cure Fight Belongs In California
• Abbott Wins Order Barring Ex-Exec From Sharing Virus Info
• Growth And Challenges For Life Sciences CRE Amid COVID-19
• Trump Admin. Sued Over Inadequate COVID-19 Reporting
• Boehringer Accused Of Withholding Royalties As Trial Starts
• A GC's Blueprint For Improving Legal Industry Diversity